INVESTOR RELATIONS

* For additional information about share price and latest announcements please review HeraMED’s page on the ASX platform View Page

HeraBEAT Plus Clinical Trial Study Details17/02/2020View
Mayo Clinic clinical study to evaluate HeraBEAT Plus10/02/2020View
HeraMED appoints US General Manager of Operations03/02/2020View
December Quarter Activities Report and Appendix 4C30/01/2020View
Notice of Extraordinary General Meeting and Proxy Form20/01/2020View
HMD accesses unique pregnancy database to strengthen OrionAI20/01/2020View
Response to ASX Aware Query20/01/2020View
Update on Voluntary Escrow for Minor Vendor Options09/01/2020View
Cleansing Notice17/12/2019View
Appendix 3B17/12/2019View
Appendix 3B12/12/2019View
A$1.42m strategic placement completed to expedite US entry10/12/2019View
Trading Halt06/12/2019View
New CPT codes allow for potential reimbursement in USA04/12/2019View
2020 Company Outlook02/12/2019View
Change of Director’s Interest Notice – Tal Slonim28/11/2019View
Change of Director’s Interest Notice – David Groberman28/11/2019View
Appendix 3B and ASX Escrow Release28/11/2019View
Indian Hospital Group Cooperates with H-Cube and HeraMED25/11/2019View
Release of Securities from ASX Escrow Restriction20/11/2019View
HeraMED Receives FDA 510(k) Clearance for HeraBEAT Device18/11/2019View
Retraction of Statements – Next Tech Stock Article15/11/2019View
Trading Halt15/11/2019View
Pause in Trade15/11/2019View
Response to ASX Price and Volume Query14/11/2019View
Trading Halt14/11/2019View
Pause in Trading14/11/2019View
Hapvida Saude (Brazil) Trial Update07/11/2019View
Appendix 3B05/11/2019View
September Quarter Activities Report and Appendix 4C30/10/2019View
Market entry for HeraBEAT and HeraCARE Progresses in India25/10/2019View
HeraCARE – the digital era of pregnancy care14/10/2019View
Collaboration agreement secured with IntMED Software Ltd ME02/10/2019View
HMD passes first stage for Israel Innovation Authority Grant24/09/2019View
HeraMED and Mayo Clinic to co-develop a New Platform17/09/2019View
Global Distribution Progress Update04/09/2019View
Appendix 3B28/08/2019View
HeraMED Solutions Operational Across Multiple Hapvida Sites28/08/2019View
Appendix 4D and Half Year Report28/08/2019View
Correction to Appendix 4C14/08/2019View
HeraMED enters the German market with initial PO secured12/08/2019View
June Quarterly Activities Report & Appendix 4C31/07/2019View
HeraCARE Investor Presentation July 201922/07/2019View
HeraCARE PRO Integrated into Hapvidas Hospital Systems01/07/2019View
HeraBEAT Australian B2C launch underway19/06/2019View
Appendix 3B14/06/2019View
Appendix 3B06/06/2019View
Appendix 3B03/06/2019View
Release of Securities from Escrow31/05/2019View
Results of Annual General Meeting29/05/2019View
Annual General Meeting Venue Room Update24/05/2019View
Dr Friedman joins HeraMED advisory board20/05/2019View
HeraMED to launch HeraBEAT in Mexico15/05/2019View
Company Presentation May 201914/05/2019View
Release of Securities from Escrow09/05/2019View
HeraMED Expands European Distribution Network Clarification08/05/2019View
HeraMED Expands European Distribution Network08/05/2019View
HeraMED begins FDA Approval Process for HeraBEAT29/04/2019View
Notice of Annual General Meeting and Proxy Form26/04/2019View
March Quarterly Activity Report & Appendix 4C26/04/2019View
Meerkats Partners for HeraBEATs Australian B2C Launch16/04/2019View
HeraMED launches HeraBEAT in the United Kingdom11/04/2019View
Response to ASX Query – Annual Report as at 31/12/1808/04/2019View
Addendum to Annual Report05/04/2019View
Appendix 4G29/03/2019View
Annual Report29/03/2019View
Orion Artificial Intelligence Presentation26/03/2019View
Dr Arturo Weschler MD Appointed to Lead Orion AI Operations26/03/2019View
Quasar Manufacturing Agreement to Deliver Scale & Efficiency13/03/2019View
Appendix 4E & Preliminary Final Report28/02/2019View
Major Brazilian Health Care Group Places Initial Pilot Order14/02/2019View
December Quarterly Activity Report & Appendix 4C31/01/2019View
Australian Distribution Agreement for 9000 HeraBEAT Units14/01/2019View
December Investor Presentation19/12/2018View
Becoming a substantial holder – Holley Pharmaceutical Group19/12/2018View
HeraMED Completes Over-Subscribed $6 Million IPO12/12/2018View
Becoming a substantial holder – Tal Slonim11/12/2018View
Becoming a substantial holder – David Groberman11/12/2018View
Initial Director’s Interest Notice – Tal Slonim11/12/2018View
Initial Director’s Interest Notice – Ronald Weinberger11/12/2018View
Initial Director’s Interest Notice – Doron Birger11/12/2018View
Initial Director’s Interest Notice – David Hinton11/12/2018View
Initial Director’s Interest Notice – David Groberman11/12/2018View
Statement of Confirmations10/12/2018View
Updated Statement of Commitments10/12/2018View
Voluntary Escrow10/12/2018View
Restricted Securities10/12/2018View
Updated Pro Forma Statement of Financial Position10/12/2018View
Capital Structure10/12/2018View
Securities Trading Policy10/12/2018View
Hera Med Ltd. Half Yearly Accounts to 30 June 201810/12/2018View
Hera Med Ltd. 2016 and 2017 Full Year Accounts10/12/2018View
Supplementary Prospectus10/12/2018View
Prospectus10/12/2018View
Constitution10/12/2018View
Appendix 1A and Information Form and Checklist10/12/2018View
Top 20 Holders10/12/2018View
Distribution Schedule10/12/2018View
ASX Notice – Admission to Official List10/12/2018View